Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIV-specific cytotoxic T lymphocytes
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This experimental adoptive cell therapy involves the infusion of HIV-specific cytotoxic T lymphocytes (CTLs) to treat HIV infection. Developed by the National Institute of Allergy and Infectious Diseases (NIAID), the therapy utilizes CTLs generated ex vivo from the lymphocytes and sibling-supplied dendritic cells of an HIV-negative donor (allogeneic). The primary objective is to bolster the recipient's immune system, particularly in patients with CD4+ T cell counts between 100-350 cells/mm³, by providing functional effector cells capable of recognizing and eliminating HIV-infected cells. This approach aims to overcome the recipient's potential inability to generate an effective endogenous CTL response due to advanced disease.
- Other names
- HIV-specific CTLsSibling-derived HIV-specific CTLsAllogeneic HIV-specific CTLs
02
Targets
pMHC (Peptide-MHC complex family)Human immunodeficiency virus envelope peptide–Major histocompatibility complex class I complexHuman immunodeficiency virus type 1 polymerase peptide–Major histocompatibility complex class I complex
Beyond the preview
Go deeper on HIV-specific cytotoxic T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIV-specific cytotoxic T lymphocytes.